神経膠腫治療の世界市場レポート 2025年

神経膠腫治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.7％で69億7,000万米ドルに成長します。予測期間の成長は、個別化治療とバイオマーカー探索、免疫療法の進歩、標的療法の統合、新規治療プラットフォームの出現、共同研究イニシアティブに起因すると考えられます。予測期間における主な動向としては、血液脳関門透過剤、モニタリングのためのリキッドバイオプシー、QOLと支持療法の重視、遺伝的・分子的サブタイプ分類、患者擁護と関与などが挙げられます。

脳腫瘍および中枢神経系腫瘍の発生率の増加が予想されることから、神経膠腫治療市場の成長が期待されます。脳腫瘍および脊髄腫瘍は、脳または中枢神経系における異常な腫瘤です。神経膠腫治療は、脳腫瘍や脊髄がんの管理において、術後に残存するがん細胞や腫瘍の一部を除去するために利用されます。例えば、2021年8月現在、米国がん協会は、米国における脳およびその他の中枢神経系がんによる2021年の推定症例数83,570例（悪性腫瘍24,530例、非悪性腫瘍59,040例を含む）、死亡数18,600例を報告しています。したがって、脳腫瘍および脊髄腫瘍の発生率の増加は、神経膠腫治療市場の成長の主要な促進要因です。

個別化医療に対する需要の高まりが、今後数年間の神経膠腫治療市場の成長を促進すると予測されています。個別化医療とは、遺伝、環境、ライフスタイルなど患者個人の特性を考慮し、治療効果や治療結果を向上させるオーダーメイドのヘルスケアアプローチです。ゲノミクスの進歩、患者のエンパワーメントの向上、治療効果の向上など、いくつかの要因がこの需要を後押ししています。神経膠腫に関連するバイオマーカーを同定することは、治療反応と治療成績の予測に極めて重要であり、各患者の特性に応じた個別化治療計画の開発を可能にします。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、2023年にFDAが希少疾患患者向けに16の新しい個別化治療を承認したと報告しました。このように、個別化医療に対する需要の高まりは、神経膠腫治療市場の主要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界神経膠腫治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の神経膠腫治療市場：成長率分析
• 世界の神経膠腫治療市場の実績：規模と成長, 2019-2024
• 世界の神経膠腫治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界神経膠腫治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の神経膠腫治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低グレード
• 高級
• 世界の神経膠腫治療市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多形性膠芽腫
• 未分化星細胞腫
• 未分化乏突起膠腫
• その他の病気
• 世界の神経膠腫治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他のルート
• 世界の神経膠腫治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 放射線治療
• 化学療法
• 標的薬物療法
• その他の治療法
• 世界の神経膠腫治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界の神経膠腫治療市場、低品位のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 星細胞腫
• 乏突起膠腫
• 混合神経膠腫
• 世界の神経膠腫治療市場、高級品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多形性膠芽腫
• 未分化星細胞腫
• 未分化乏突起膠腫

第7章 地域別・国別分析

• 世界の神経膠腫治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の神経膠腫治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経膠腫治療市場：競合情勢
• 神経膠腫治療市場：企業プロファイル
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sun Pharmaceutical Industries Ltd.
• Arbor Pharmaceuticals LLC
• Amneal Pharmaceuticals Inc.
• Karyopharm Therapeutics Inc.
• Bristol-Myers Squibb Co.
• Rigel Pharmaceuticals Inc.
• Sumitomo Dainippon Pharma Oncology Inc.
• Emcure Pharmaceuticals Ltd.
• Novartis AG
• AstraZeneca plc
• Eli Lilly and Company
• Sanofi S.A.
• Johnson & Johnson
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 神経膠腫治療市場2029：新たな機会を提供する国
• 神経膠腫治療市場2029：新たな機会を提供するセグメント
• 神経膠腫治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Glioma treatment involves interventions aimed at reducing symptoms, controlling and removing tumors, and mitigating long-term damage to the brain or spinal cord. These treatments are crucial for eliminating any remaining glioma cells post-surgery.

Glioma treatment encompasses two main types, low-grade and high-grade. Low-grade gliomas are tumors that develop in the brain and typically exhibit slow growth. Diseases such as glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others are addressed through various routes of administration, including oral and parenteral methods. These conditions can be treated with diverse surgeries, including radiation therapy, chemotherapy, targeted drug therapy, and others. The end users of glioma treatment include hospitals, specialty clinics, and other healthcare facilities.

The glioma treatment market research report is one of a series of new reports from The Business Research Company that provides glioma treatment market statistics, including glioma treatment industry global market size, regional shares, competitors with a glioma treatment market share, detailed glioma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the glioma treatment industry. This glioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glioma treatment market size has grown strongly in recent years. It will grow from$5.06 billion in 2024 to $5.39 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the risen incidence of gliomas, advancements in molecular understanding, evolution of standard therapies, clinical trials and research progress, and improved imaging and diagnostic techniques

The glioma treatment market size is expected to see strong growth in the next few years. It will grow to $6.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized therapies and biomarker discovery, immunotherapeutic advancements, integration of targeted therapies, the emergence of novel therapeutic platforms, and collaborative research initiatives. Major trends in the forecast period include blood-brain barrier penetrating agents, liquid biopsy for monitoring, focus on the quality of life and supportive care, genetic and molecular subtyping, patient advocacy and involvement.

The anticipated increase in the incidence of brain and CNS tumors is expected to drive the growth of the glioma treatment market. Brain and spinal cord tumors are abnormal masses in the brain or central nervous system. Glioma treatment is utilized in the management of brain and spinal cord cancer to eliminate any residual cancer cells or portions of the tumor post-surgery. For instance, as of August 2021, the American Cancer Society reported an estimated 83,570 cases, including 24,530 malignant tumors and 59,040 nonmalignant tumors, with 18,600 deaths from brain and other CNS cancers in the United States for the year 2021. Hence, the increasing incidence of brain and spinal cord tumors is a key driver for the growth of the glioma treatment market.

The rising demand for personalized medicine is projected to drive the growth of the glioma treatment market in the coming years. Personalized medicine involves a tailored healthcare approach that considers individual patient characteristics, such as genetics, environment, and lifestyle, to improve treatment effectiveness and outcomes. Several factors are fueling this demand, including advancements in genomics, increased patient empowerment, and enhanced treatment efficacy. Identifying biomarkers associated with gliomas is crucial for predicting treatment responses and outcomes, allowing for the development of personalized treatment plans that cater to the unique characteristics of each patient. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a significant increase from six approvals in 2022. Thus, the growing demand for personalized medicine is a key driver of the glioma treatment market.

Product innovation is a significant trend gaining traction in the glioma treatment market. Leading companies in this sector are introducing new and innovative products to maintain their competitive edge. For example, in June 2024, Servier Pharmaceuticals, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This approval marks a notable milestone as it represents the first targeted therapy for Grade 2 IDH-mutant glioma. Vorasidenib is a dual inhibitor that targets mutations in isocitrate dehydrogenase (IDH) 1 and 2, which are frequently associated with gliomas. These mutations lead to the production of 2-hydroxyglutarate (2-HG), a metabolite that fosters tumor growth and survival. By inhibiting these enzymes, vorasidenib lowers 2-HG levels, potentially slowing the progression of the tumor.

Prominent companies in the glioma treatment market are concentrating on the introduction of advanced targeted therapy solutions, particularly combination medicines, to gain a competitive advantage. Combination medicines aim to offer a more effective and convenient treatment option for patients dealing with complex medical conditions such as glioma. For instance, in May 2023, Novartis AG, a Swiss pharmaceutical corporation, received approval from the U.S. Food and Drug Administration (FDA) for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of pediatric patients (at least one year old) with low-grade gliomas (LGGs) harboring a BRAF V600E mutation and requiring systemic therapy. This approval marks the first combination targeted medication endorsed for the treatment of BRAF V600E LGG in pediatric patients, offering a potential new standard of care therapy option. Pediatric LGG is the most prevalent type of pediatric brain cancer, with BRAF V600 mutations present in 15-25% of cases, associated with poor survival outcomes and less favorable responses to chemotherapy.

In February 2023, Kite, a global biopharmaceutical company based in the U.S., completed the acquisition of Tmunity Therapeutics for an undisclosed amount. This strategic move enhances Kite's internal capabilities in cell therapy research by incorporating additional pipeline assets. The acquisition provides access to pre-clinical and clinical programs, including an 'armored' CAR T technology platform, with the potential to enhance the anti-tumor activity of various CAR-Ts. Tmunity Therapeutics Inc., the acquired company, focuses on developing innovative products for the treatment of diffuse intrinsic pontine glioma.

Major companies operating in the glioma treatment market include Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Emcure Pharmaceuticals Ltd., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.

North America was the largest region in the glioma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global glioma treatment market report during the forecast period. The regions covered in the glioma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The glioma treatment market includes revenues earned by entities by cerebral spinal fluid diversion, internal radiation therapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glioma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glioma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glioma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glioma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Low-Grade; High-Grade
• 2) By Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Other Diseases
• 3) By Route Of Administration: Oral; Parenteral; Other Routes
• 4) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Drug Therapy; Other Treatments
• 5) By End-User: Hospitals; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Low-Grade: Astrocytoma; Oligodendroglioma; Mixed Glioma
• 2) By High-Grade: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma
• Companies Mentioned: Merck & Co Inc.; Amgen Inc.; F Hoffmann-La Roche AG; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glioma Treatment Market Characteristics

3. Glioma Treatment Market Trends And Strategies

4. Glioma Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Glioma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glioma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glioma Treatment Market Growth Rate Analysis
• 5.4. Global Glioma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glioma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glioma Treatment Total Addressable Market (TAM)

6. Glioma Treatment Market Segmentation

• 6.1. Global Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Grade
• High-Grade
• 6.2. Global Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glioblastoma Multiforme
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Other Diseases
• 6.3. Global Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.4. Global Glioma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Drug Therapy
• Other Treatments
• 6.5. Global Glioma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End Users
• 6.6. Global Glioma Treatment Market, Sub-Segmentation Of Low-Grade, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Astrocytoma
• Oligodendroglioma
• Mixed Glioma
• 6.7. Global Glioma Treatment Market, Sub-Segmentation Of High-Grade, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glioblastoma Multiforme
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma

7. Glioma Treatment Market Regional And Country Analysis

• 7.1. Global Glioma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glioma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glioma Treatment Market

• 8.1. Asia-Pacific Glioma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glioma Treatment Market

• 9.1. China Glioma Treatment Market Overview
• 9.2. China Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glioma Treatment Market

• 10.1. India Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glioma Treatment Market

• 11.1. Japan Glioma Treatment Market Overview
• 11.2. Japan Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glioma Treatment Market

• 12.1. Australia Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glioma Treatment Market

• 13.1. Indonesia Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glioma Treatment Market

• 14.1. South Korea Glioma Treatment Market Overview
• 14.2. South Korea Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glioma Treatment Market

• 15.1. Western Europe Glioma Treatment Market Overview
• 15.2. Western Europe Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glioma Treatment Market

• 16.1. UK Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glioma Treatment Market

• 17.1. Germany Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glioma Treatment Market

• 18.1. France Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glioma Treatment Market

• 19.1. Italy Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glioma Treatment Market

• 20.1. Spain Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glioma Treatment Market

• 21.1. Eastern Europe Glioma Treatment Market Overview
• 21.2. Eastern Europe Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glioma Treatment Market

• 22.1. Russia Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glioma Treatment Market

• 23.1. North America Glioma Treatment Market Overview
• 23.2. North America Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glioma Treatment Market

• 24.1. USA Glioma Treatment Market Overview
• 24.2. USA Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glioma Treatment Market

• 25.1. Canada Glioma Treatment Market Overview
• 25.2. Canada Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glioma Treatment Market

• 26.1. South America Glioma Treatment Market Overview
• 26.2. South America Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glioma Treatment Market

• 27.1. Brazil Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glioma Treatment Market

• 28.1. Middle East Glioma Treatment Market Overview
• 28.2. Middle East Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glioma Treatment Market

• 29.1. Africa Glioma Treatment Market Overview
• 29.2. Africa Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glioma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Glioma Treatment Market Competitive Landscape
• 30.2. Glioma Treatment Market Company Profiles
  • 30.2.1. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Glioma Treatment Market Other Major And Innovative Companies

• 31.1. Sun Pharmaceutical Industries Ltd.
• 31.2. Arbor Pharmaceuticals LLC
• 31.3. Amneal Pharmaceuticals Inc.
• 31.4. Karyopharm Therapeutics Inc.
• 31.5. Bristol-Myers Squibb Co.
• 31.6. Rigel Pharmaceuticals Inc.
• 31.7. Sumitomo Dainippon Pharma Oncology Inc.
• 31.8. Emcure Pharmaceuticals Ltd.
• 31.9. Novartis AG
• 31.10. AstraZeneca plc
• 31.11. Eli Lilly and Company
• 31.12. Sanofi S.A.
• 31.13. Johnson & Johnson
• 31.14. AbbVie Inc.
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Glioma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glioma Treatment Market

34. Recent Developments In The Glioma Treatment Market

35. Glioma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Glioma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glioma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glioma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer